Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

The E.mbrace study is a randomized, double-blind, placebo-controlled, multicenter, interventional phase 3 study evaluating the efficacy, safety, and immunogenicity of a single dose of the vaccine ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Tivic Health Systems, Inc., (Nasdaq: TIVC) today announced it has acquired worldwide exclusive license rights from Statera Biopharma (OTC: STAB) to the late-stage Toll-like Receptor 5 (TLR5) agonist ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, February 20th. Analysts expect Prelude Therapeutics to ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a research report issued on Tuesday,Benzinga reports.

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...